Anheuser-Busch InBev vs Coca Cola
BUD and KO side by side, both in beverages. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BUD and KO compare
Coca Cola grew revenue faster over the last twelve months (7.1% versus −0.75% for Anheuser-Busch InBev).
Coca Cola keeps more of each dollar of sales as profit, with a net margin of 28.7% compared with 11.5% at Anheuser-Busch InBev.
Coca Cola pays a dividend yielding 2.2%; Anheuser-Busch InBev does not pay one.
Coca Cola scores higher on the StockData Score (21 against 5 for Anheuser-Busch InBev), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BUD | KO |
|---|---|---|
| Size and price | ||
| Market cap | – | $420B |
| Share price | $84.08 | $97.57 |
| Change, 1 year | 32.7% | 38.4% |
| Change, 5 years | 43.6% | 77.0% |
| Beta (5Y) | 0.51 | 0.33 |
| Employees | 137K | 70K |
| StockData Score | ||
| Total score | 5 | 21 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 5 (better) |
| Performance score | 4 | 6 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 28.7× |
| P/S | – | 8.2× |
| P/B | – | 11.2× |
| EV/EBITDA | – | 27.5× |
| P/FCF | – | 29.4× |
| PEG | – | 2.48 |
| FCF yield | – | 3.4% |
| Fair value | – | $75.71 |
| Margin of safety | – | −28.9% |
| Growth | ||
| Revenue growth (TTM) | −0.75% | 7.1% (better) |
| Revenue growth, 5Y average | 4.8% | 7.7% (better) |
| Net income growth (TTM) | 16.8% (better) | 12.3% |
| EPS growth (TTM) | 18.5% (better) | 12.6% |
| EPS growth, 5Y average | 37.5% (better) | 11.2% |
| Profitability | ||
| Gross margin | 55.9% | 62.3% (better) |
| Operating margin | 26.0% | 30.0% (better) |
| Net margin | 11.5% | 28.7% (better) |
| FCF margin | 18.9% | 28.0% (better) |
| Return on equity | 7.9% | 42.6% (better) |
| Return on invested capital | 14.5% | 19.5% (better) |
| Financial health | ||
| Debt / equity | – | 1.11 |
| Net debt / EBITDA | – | 1.70 |
| Interest coverage | 3.0× | 10.0× (better) |
| Current ratio | 0.66 | 1.38 (better) |
| Altman Z-score | – | 5.84 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Dividend yield | – | 2.2% |
| Payout ratio | 66.4% | 76.8% |
| Years of dividend growth | – | 16 |
| Dividend growth, 5Y average | – | 4.5% |
| Buyback yield | – | 0.14% |
| Shareholder yield | – | 2.3% |
| Ownership | ||
| Held by institutions | 5.3% | 75.3% |
| Held by insiders | – | 0.22% |
| Insider net buying, 12 months | – | −$248M |
| Superinvestors holding | 1 | 5 (better) |
| Short interest, % of float | – | 1.1% |
Go deeper
- BUD stock overview
- BUD income statement
- BUD valuation and score
- KO stock overview
- KO income statement
- KO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.